Amt für Gemeinden und Raumordnung

Recent papers from Amt für Gemeinden und Raumordnung

1. Exposure-response and dose simulation of belantamab mafodotin in combination with standards of care in patients with relapsed/refractory multiple myelomaHaematologica · 2026
2. Simulation Framework to Investigate Efficacy and Ocular Safety of Belantamab Mafodotin Combinations in Relapsed/Refractory Multiple MyelomaCPT Pharmacometrics & Systems Pharmacology · 2026
3. A phase Ia/Ib trial of FAP-Dox (AVA6000), a fibroblast activation protein (FAP)–released doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors and activity against salivary gland cancers.Journal of Clinical Oncology · 2026
4. Women and Herpes Zoster in the United States: Risk and Prevention Management—A Narrative ReviewWomen s Health Reports · 2026
5. In silico typing maps the natural diversity of Escherichia coli transporter-dependent capsulesNature Microbiology · 2026
6. Association Between Transfusion Status, Hemoglobin Levels, and Patient‐Reported Outcomes in Myelofibrosis: A Post Hoc Clinical Trial AnalysisCancer Medicine · 2026
7. Abstract 7193: Short exposure to TTFields potentiates radiation response in glioblastoma via downregulation of DNA repair pathwaysCancer Research · 2026
8. Abstract 5836: Augmented antitumor activity of Tumor Treating Fields (TTFields) with anti-VEGFR and docetaxel treatment in a lung cancer mouse modelCancer Research · 2026
9. Abstract 5835: Treatment of pancreatic cancer cells with Tumor Treating Fields (TTFields) and KRAS inhibitorsCancer Research · 2026
10. Abstract 5846: AVA6103 is a FAP-enabled pre|CISION®peptide-drug conjugate delivering sustained release of exatecan in the tumor microenvironment with potent antitumor activityCancer Research · 2026
11. Abstract 4456: Tumor Treating Fields (TTFields) potentiate antitumor and immune responses to standard immunochemotherapy in non-small cell lung cancer models.Cancer Research · 2026
12. Abstract 5706: Modeling the influence of Tumor Treating Fields (TTFields) treatment usage time and break patterns on therapeutic outcomesCancer Research · 2026
13. Abstract 4455: Efficacy of Tumor Treating Fields (TTFields) together with standard chemotherapy and PD-L1 blockage in preclinical models of small cell lung carcinoma.Cancer Research · 2026
14. Abstract 5870: Momelotinib: Unique polypharmacology and novel combination strategies for myelofibrosis and beyondCancer Research · 2026
15. Abstract 1277: Overcoming glioblastoma resistance by targeting its heterogeneity with a synergistic approach: TTFields stimulation and tmCLIC1 impairment.Cancer Research · 2026
16. Ruxolitinib treatment for myelofibrosis with anemia: a retrospective assessment of real-world patient characteristics, treatment patterns, and survival.2026
17. Overall survival with momelotinib vs. best available therapy in patients with ruxolitinib-experienced myelofibrosis: a matching-adjusted indirect comparisonAnnals of Hematology · 2026
18. A Revised Classification of FVIII Concentrates: Rationale and Novel MetricsBlood Advances · 2026
19. Dual transfusion independence and spleen volume reduction is associated with overall survival in patients with myelofibrosis treated with momelotinib: Post hoc analyses of SIMPLIFY-1 and MOMENTUMBlood · 2025
20. Spatial patterns of fat within the deep multifidus as a biomarker for chronic low back painThe Spine Journal · 2025